Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy

Mahmood Rasool; Arif Malik; Muhammad Saeed Qureshi; Riaz Ahmad; Abdul Manan; Muhammad Asif; Muhammad Imran Naseer; Peter Natesan Pushparaj

doi:10.6026/97320630010703

Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy

Bioinformation. 2014 Nov 27;10(11):703-7. doi: 10.6026/97320630010703. eCollection 2014.

Authors

Mahmood Rasool¹, Arif Malik², Muhammad Saeed Qureshi², Riaz Ahmad², Abdul Manan², Muhammad Asif³, Muhammad Imran Naseer¹, Peter Natesan Pushparaj¹

Affiliations

¹ Center of Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz University, Jeddah, Saudi Arabia.
² Institute of Molecular Biology and Biotechnology (IMBB), the University of Lahore, Lahore, Pakistan.
³ Department of Biotechnology and Informatics, BUITEMS, Quetta, Pakistan.

Abstract

Tumor lysis syndrome (TLS) is characterized by hyperuricaemia, hyperphosphatemia, hyperkalaemia, as well as hypocalcaemia due to the breakdown of tumor cells undergoing cancer therapy (chemo/radio). Therefore it is of interest to evaluate oxidative stress using selective biological markers [Malondialdehyde (MDA), Superoxide Dismutase (SOD), Glutathione (GSH) and Catalase (CAT)] in TLS. We report the marked differences (statistically significant with control) observed among a selected set of biomarkers of oxidative stress (MDA = 8.66±1.37; SOD = 0.15±0.11; GSH = 2.25±.77; CAT = 0.76±.57) in TLS patients in addition to other conventional biomarkers. Moreover, correlation was investigated among the parameters of oxidative stress and other circulating biomarkers of TLS. Data suggest the use of SOD, MDA, and GSH as potential diagnostic biomarker for TLS with other biomarkers.

Keywords: GSH; MDA; SOD; Tumor lysis syndrome (TLS); hyperkalaemia; hyperphosphatemia; hyperuricaemia; hypocalcaemia; oxidative stress.